{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T02:52:44Z","timestamp":1794883964785,"version":"4.9.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,5,10]],"date-time":"2006-05-10T00:00:00Z","timestamp":1147219200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2006,9,25]]},"DOI":"10.1007\/s11060-006-9162-9","type":"journal-article","created":{"date-parts":[[2006,5,9]],"date-time":"2006-05-09T09:13:46Z","timestamp":1147166026000},"page":"97-100","source":"Crossref","is-referenced-by-count":65,"title":["Levetiracetam therapy in patients with brain tumour and epilepsy"],"prefix":"10.1007","volume":"80","author":[{"given":"Marta","family":"Maschio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorenzo","family":"Albani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostino","family":"Baruzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Zarabla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Dinapoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Pompili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine Maria","family":"Carapella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Occhipinti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Jandolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,5,10]]},"reference":[{"key":"9162_CR1","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJM200101113440207","volume":"344","author":"L Angelis De","year":"2001","unstructured":"De Angelis L (2001) Brain tumors. N Engl J Med 344:114\u2013123","journal-title":"N Engl J Med"},{"key":"9162_CR2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1017\/S0317167100053336","volume":"30","author":"WP Mason","year":"2003","unstructured":"Mason WP (2003) Anticonvulsant prophylaxis for patients with brain tumours: insights from clinical trials. Can J Neurol Sci 30:89\u201390","journal-title":"Can J Neurol Sci"},{"key":"9162_CR3","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/01.cco.0000127720.17558.38","volume":"16","author":"J Hildebrand","year":"2004","unstructured":"Hildebrand J (2004) Management of epileptic seizures. Curr Opin Oncol 16:314\u2013317","journal-title":"Curr Opin Oncol"},{"key":"9162_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s007010050001","volume":"142","author":"A Beaumont","year":"2000","unstructured":"Beaumont A, Whittle IR (2000) The pathogenesis of tumour associated epilepsy. Acta Neurochir (Wien) 142:1\u201315","journal-title":"Acta Neurochir (Wien)"},{"issue":"Suppl 1","key":"9162_CR5","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1007\/s10072-005-0404-y","volume":"26","author":"M Riva","year":"2005","unstructured":"Riva M (2005) Brain tumoral epilepsy: a review. Neurol Sci 26(Suppl 1):S40\u2013S42","journal-title":"Neurol Sci"},{"key":"9162_CR6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11060-004-2338-2","volume":"72","author":"S Oberndorfer","year":"2005","unstructured":"Oberndorfer S, Piribauer M, Marosi C, Larhmann H, Hitzenberger P, Grisold W (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol 72:255\u2013260","journal-title":"J Neurooncol"},{"key":"9162_CR7","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1212\/WNL.54.10.1886","volume":"54","author":"MJ Glantz","year":"2000","unstructured":"Glantz MJ, Cole BF, Forsyth PA, et al (2000) Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neurology 54:1886\u20131893","journal-title":"Neurology"},{"key":"9162_CR8","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1046\/j.1528-1157.2001.28900.x","volume":"42","author":"NR Temkin","year":"2001","unstructured":"Temkin NR (2001) Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. Epilepsia 42:515\u2013524","journal-title":"Epilepsia"},{"key":"9162_CR9","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S1474-4422(03)00435-6","volume":"2","author":"CJ Vecht","year":"2003","unstructured":"Vecht CJ, Wagner GL, Wilms EB (2003) Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2:404\u2013409","journal-title":"Lancet Neurol"},{"key":"9162_CR10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00003495-200060010-00003","volume":"60","author":"A Sabers","year":"2000","unstructured":"Sabers A, Gram L (2000) Newer anticonvulsants: comparative review of drug interactions and adverse effects. Drugs 60:23\u201333","journal-title":"Drugs"},{"key":"9162_CR11","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1212\/01.wnl.0000168903.09277.8f","volume":"65","author":"J Hildebrand","year":"2005","unstructured":"Hildebrand J, Lecaille C, Perennes J, Delattre JY (2005) Epileptic seizures during follow-up of patients treated for primary brain tumors. Neurology 65:212\u2013215","journal-title":"Neurology"},{"key":"9162_CR12","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S1059-1311(03)00096-7","volume":"12","author":"GL Wagner","year":"2003","unstructured":"Wagner GL, Wilms EB, Van Donselaar CA, Vecht ChJ (2003) Levetiracetam: preliminary experience in patients with primary brain tumours. Seizure 12:585\u2013586","journal-title":"Seizure"},{"key":"9162_CR13","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1017\/S0317167100038853","volume":"23","author":"JR Perry","year":"1996","unstructured":"Perry JR, Sawka C (1996) Add-on gabapentin for refractory seizures in patients with brain tumours. Can J Neurol Sci 23:128\u2013131","journal-title":"Can J Neurol Sci"},{"key":"9162_CR14","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1345\/aph.1A032","volume":"36","author":"TE Welty","year":"2002","unstructured":"Welty TE, Gidal BE, Ficker DM, Privitera MD (2002) Levetiracetam: a different approach to the pharmacotherapy of epilepsy. Ann Pharmacother 36:296\u2013304","journal-title":"Ann Pharmacother"},{"key":"9162_CR15","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2165\/00003088-200443110-00002","volume":"43","author":"PN Patsalos","year":"2004","unstructured":"Patsalos PN (2004) Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet 43:707\u2013724","journal-title":"Clin Pharmacokinet"},{"key":"9162_CR16","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00007691-200408000-00006","volume":"26","author":"M Contin","year":"2004","unstructured":"Contin M, Albani F, Riva R, Baruzzi A (2004) Levetiracetam therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther Drug Monit 26:375\u2013379","journal-title":"Ther Drug Monit"},{"key":"9162_CR17","unstructured":"Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events v3.0, DCTD, NCI, NIH, DHHS, December 12, 2003; http:\/\/www.ctep.cancer.gov; last accessed January 11, 2006"},{"key":"9162_CR18","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/annonc\/mdg502","volume":"14","author":"A Pace","year":"2003","unstructured":"Pace A, Vidiri A, Gali\u00e9 E, Carosi M, Telera S, Cianciulli AM, Canalini P, Giannarelli D, Jandolo B, Carapella CM (2003) Temozolamide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol 14:1722\u20131726","journal-title":"Ann Oncol"},{"key":"9162_CR19","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/annonc\/mdg371","volume":"14","author":"M Brada","year":"2003","unstructured":"Brada M, Viviers L, Abson C, Hines F, Britton J, Ashley S, Sardell S, Traish D, Gonsalves A, Wilkins P, Westbury C (2003) Phase II of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 14:1715\u20131721","journal-title":"Ann Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-006-9162-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-006-9162-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-006-9162-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T04:18:56Z","timestamp":1559362736000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-006-9162-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,10]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,9,25]]}},"alternative-id":["9162"],"URL":"https:\/\/doi.org\/10.1007\/s11060-006-9162-9","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5,10]]}}}